MedTrace Logo

Fruquintinib DDI Study With P-gp and BCRP Substrates

NCT05368805 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2022-10-06

No results posted yet for this study

Summary

Fruquintinib DDI Study with P-gp and BCRP Substrates

Conditions

Interventions

DRUG

Fruquintinib

Fruquintinib will be administered as a single oral 5mg dose on the morning of day 5

DRUG

Dabigatran Etexilate

Dabigatran Etexilate will be administered as a single oral dose 150mg on the morning of day 1 and morning of day 5

DRUG

Rosuvastatin

Rosuvastatin will be administered as a single oral dose 10mg on the morning of day 1 and the morning of day 5

Sponsors & Collaborators

  • Hutchmed

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-03-02
Primary Completion
2022-04-22
Completion
2022-04-22
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05368805 on ClinicalTrials.gov